In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

Claims 1-7 (cancelled)

Claim 8. (original) A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and a 5-$HT_{1B/1D}$ receptor agonist, or a pharmaceutically acceptable salt thereof.

Claim 9. (original) The combination according to claim 8 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.

Claim 10. (currently amended) The combination according to claim[[s]] 8 [[or 9]] wherein the 5-$HT_{1B/1D}$ receptor agonist is selected from zolmitriptan, sumatriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and almotriptan or a pharmaceutically acceptable salt thereof.

Claim 11. (currently amended) The combination according to claim 8 ~~any one of claims 8-10~~ wherein the endothelin receptor antagonist is ZD4054, or a pharmaceutically acceptable salt thereof, and the 5-$HT_{1B/1D}$ receptor agonist is zolmitriptan, or a pharmaceutically acceptable salt thereof.

Claim 12. (cancelled)

Claim 13. (currently amended) A pharmaceutical composition comprising the combination according to ~~any one of~~ claim[[s]] 8[[-11]], in association with a pharmaceutically acceptable diluent or carrier.

Claims 14-20 (cancelled)

Claim 21. (new) The combination according to claim 9 wherein the 5-$HT_{1B/1D}$ receptor agonist is selected from zolmitriptan, sumatriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and almotriptan or a pharmaceutically acceptable salt thereof.

Claim 22. (new) A method of treating cancer, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a combination according to claim 8.

Claim 23. (new) The method according to claim 22 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.

Claim 24. (new) The method according to claim 22 wherein the cancer is prostate cancer.

Claim 25. (new) The method according to claim 22 wherein the cancer is in a metastatic state.

Claim 26. (new) The method according to claim 22 wherein the cancer is in a non-metastatic state.

Claim 27. (new) The method according to claim 22 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.

Claim 28. (new) A method of treating or preventing headaches that result from administering an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, which comprises administering a 5-$HT_{1B/1D}$ receptor agonist, or a pharmaceutically acceptable salt thereof, to a warm-blooded animal, such as man.

Claim 29. (new) The method according to claim 28 wherein the 5-$HT_{1B/1D}$ receptor agonist is selected from zolmitriptan, sumatriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and almotriptan or a pharmaceutically acceptable salt thereof.

Claim 30. (new) The method according to claim 28 wherein the 5-$HT_{1B/1D}$ receptor agonist is zolmitriptan or a pharmaceutically acceptable salt thereof.

Claim 31. (new) The method according to claim 28 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.

Claim 32. (new) The method according to claim 29 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.

Claim 33. (new) The method according to claim 30 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ZD1611, ambrisentan, tezosentan, darusentan, *N*-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-*N*,3,3-trimethylbutanamide and *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054) or a pharmaceutically acceptable salt thereof.

Claim 34. (new) The method according to claim 28 wherein the endothelin receptor antagonist is selected from ZD4054.

Claim 35. (new) The method according to claim 29 wherein the endothelin receptor antagonist is selected from ZD4054.

Claim 36. (new) The method according to claim 30 wherein the endothelin receptor antagonist is selected from ZD4054.